Evidence map›Paper›PMID 29143650›Full record

ArticleParasites & vectors2017

Microfilarial reduction following ProHeart® 6 and ProHeart® SR-12 treatment in dogs experimentally inoculated with a resistant isolate of Dirofilaria immitis.

Tom L McTier, Aleah Pullins, Gregory A Inskeep, Genevieve Gagnon, Huihao Fan, Adam Schoell, Tara Bidgood, Joyce Login, Patrick Meeus

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tom L McTierZoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA. tom.mctier@zoetis.com.
Aleah PullinsZoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
Gregory A InskeepZoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
Genevieve GagnonZoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
Huihao FanZoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
Adam SchoellZoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
Tara BidgoodVeterinary Operations, Zoetis, 10 Sylvan Way, Parsippany, NJ, 07054, USA.
Joyce LoginVeterinary Operations, Zoetis, 10 Sylvan Way, Parsippany, NJ, 07054, USA.
Patrick MeeusZoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
Zoetis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmerging resistance of heartworms (Dirofilaria immitis) to macrocyclic lactone (ML) preventives is an increasing concern for veterinarians, pet owners and animal health companies that supply heartworm preventives, with recent reports of resistant isolates identified from the Mississippi Delta region of the United States. Products that are effective in eliminating microfilariae (MF) in dogs harboring resistant heartworm infections could be important in reducing the spread of heartworm resistance. The current study was conducted to investigate the potential for ProHeart® 6 (PH 6; Zoetis) and ProHeart® SR-12 (PH 12; Zoetis) to reduce MF in dogs experimentally inoculated with an isolate of D. immitis (ZoeMo-2012) confirmed to be resistant to MLs.

methodsTwenty-three dogs with preexisting heartworm infections (via surgical transplantation) were randomly allocated to four groups based on pretreatment (Day -14) MF counts. On Day 0, dogs received a subcutaneous injection of either saline (placebo-treated control, 6 dogs), PH 6 (0.17 mg/kg, 6 dogs), PH 12 (0.5 mg/kg, 5 dogs) or a single oral dose of moxidectin powder in a gelatin capsule (0.25 mg/kg, 6 dogs). All dogs were bled for MF counts (modified Knott's test) on Days 0 (pretreatment), 1, 3, 7, 14, 21, 28, 42, 56, and 84. Dogs in control and PH 6 groups were also bled for MF counts on Days 112, 140, and 168. No adverse events associated with treatment were observed for any dog.

resultsAverage reductions in MF counts compared with controls for PH 6 were 9.7% on Day 1, increasing to 75.0% on Day 7, and further to 86.5% on Day 28. On Day 42, average MF reduction increased to 90.3%. Reductions increased further over the next several months with reductions of 91.3, 96.8, 96.6, and 98.9% on Days 56, 84, 112, and 140, respectively. On Day 168, the reduction was 99.3% (P < 0.0001). Average reductions in MF counts compared with controls for PH 12 were 20.9% on Day 1, increasing to 78.9% on Day 7, and further to 91.2% on Day 28. On Day 84, the reduction was 96.9%. For dogs receiving a single oral moxidectin (0.25 mg/kg) on Day 0, reductions in MF were 86.3% on Day 1 and fluctuated between 74.4 and 83.6% through Day 28. On Days 42 and 56, percentage reductions were 87.1 and 81.8%, respectively, and 92.6% at the final time point (Day 84).

conclusionBoth PH 6 and PH 12 were highly effective in reducing the MF levels of a confirmed ML-resistant heartworm isolate following a single dose.

Indexed as

AnimalsDirofilaria immitisDirofilariasisDog DiseasesDogsDrug EvaluationFemaleFilaricidesLactonesMaleMicrofilariaeMississippiFilaricidesLactonesCanine heartwormDirofilaria immitisMacrocyclic lactoneMicrofilariaMoxidectinProHeart® 6ProHeart® SR-12Resistance

Identifiers

PMID29143650
PMCPMC5688434
OpenAlexW2767643954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.